Loading organizations...
Syncona is a healthcare company that founds, builds, and funds life science businesses. It develops a diversified portfolio of companies focused on advancing innovative treatments, especially in gene and cell therapy, to address significant unmet medical needs. It identifies promising scientific breakthroughs and cultivates them into leading enterprises.
The Wellcome Trust established Syncona in 2012, recognizing an opportunity to translate world-class academic research into impactful patient therapies. This initiative aimed to bridge the gap between discovery and commercialization, partnering with academic founders and experienced management to bring novel treatments to fruition.
Syncona's efforts ultimately benefit patients by delivering transformative medical solutions for severe diseases. Its long-term vision is to establish a sustainable portfolio of global leaders in life science, ensuring that groundbreaking scientific insights are developed into effective treatments with substantial patient impact.
Key people at Syncona.
Syncona was founded in 2012 by Martin Murphy (Co-Founder & Chief Executive Officer).
Syncona was founded in 2012 by Martin Murphy (Co-Founder & Chief Executive Officer).
Key people at Syncona.
Syncona has 6 tracked investments across 5 companies. The latest tracked deal is $75.0M Series C in Beacon Therapeutics in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 8, 2026 | Beacon Therapeutics | $75.0M Series C | — | Oxford Science Enterprises, Rusty Kelley, Advent Life Sciences, Forbion |
| Nov 19, 2020 | Achilles Therapeutics | $69.8M Series C | Boxer Capital, OrbiMed | Forbion, Invus, Perceptive Advisors, RA Capital Management, Redmile Group |
| Apr 24, 2020 | SwanBio Therapeutics | $52.0M Series A Extension | Partners Innovation Fund, Syncona | — |
| Nov 1, 2016 | Achilles Therapeutics | $16.1M Other Equity | Cancer Research Horizons, Syncona, UCL | Francis Crick Institute, UCL Business |
| Mar 1, 2016 | Cambridge Epigenetix | $21.0M Series B | GV | Andreessen Horowitz, Craft Ventures, Creandum, Dawn Capital, Floodgate, F Prime Capital, Greylock, Erik Nordlander, Khosla Ventures, LAUNCH, Sequoia Capital, Vendep Capital, Webb Investment Network, Dharmesh Shah, Nikolaj Nyholm, Pete Moore, University OF Cambridge |
| Nov 1, 2015 | Nightstar Therapeutics | $35.0M Series B | David Mott | Mott Family Capital, ALI Behbahani, OrbiMed |
